2/4
07:17 am
exel
Exelixis (NASDAQ:EXEL) was given a new $44.00 price target on by analysts at Barclays PLC.
Low
Report
Exelixis (NASDAQ:EXEL) was given a new $44.00 price target on by analysts at Barclays PLC.
2/3
08:03 am
exel
Exelixis (NASDAQ:EXEL) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $52.00 price target on the stock.
Low
Report
Exelixis (NASDAQ:EXEL) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $52.00 price target on the stock.
2/2
10:03 am
exel
Exelixis (NASDAQ:EXEL) was given a new $49.00 price target on by analysts at Morgan Stanley.
Medium
Report
Exelixis (NASDAQ:EXEL) was given a new $49.00 price target on by analysts at Morgan Stanley.
2/2
08:12 am
exel
Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer [Yahoo! Finance]
Low
Report
Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer [Yahoo! Finance]
2/2
08:00 am
exel
Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer
Medium
Report
Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer
2/2
07:18 am
exel
Alterome Therapeutics Appoints Leo Faoro, MD, MBA, as Chief Medical Officer [Yahoo! Finance]
Medium
Report
Alterome Therapeutics Appoints Leo Faoro, MD, MBA, as Chief Medical Officer [Yahoo! Finance]
2/1
08:26 pm
exel
Exelixis Files Zanzalintinib With FDA As Valuation Signals Upside Potential [Yahoo! Finance]
Low
Report
Exelixis Files Zanzalintinib With FDA As Valuation Signals Upside Potential [Yahoo! Finance]
2/1
10:33 am
exel
Assessing Exelixis (EXEL) Valuation After Recent Share Price Volatility [Yahoo! Finance]
Low
Report
Assessing Exelixis (EXEL) Valuation After Recent Share Price Volatility [Yahoo! Finance]
2/1
07:53 am
exel
Is Exelixis (EXEL) Using Zanzalintinib To Redefine Its Post-Cabometyx Oncology Strategy? [Yahoo! Finance]
Low
Report
Is Exelixis (EXEL) Using Zanzalintinib To Redefine Its Post-Cabometyx Oncology Strategy? [Yahoo! Finance]
1/31
07:22 pm
exel
2 Stocks That Could Soar This Year [Yahoo! Finance]
Low
Report
2 Stocks That Could Soar This Year [Yahoo! Finance]
1/28
10:11 pm
exel
Exelixis: Stock Likely To Go Higher On A Possible Key FDA Approval [Seeking Alpha]
Low
Report
Exelixis: Stock Likely To Go Higher On A Possible Key FDA Approval [Seeking Alpha]
1/27
04:05 pm
exel
Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026
Low
Report
Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026
1/27
08:04 am
exel
Exelixis (NASDAQ:EXEL) had its price target raised by analysts at HC Wainwright from $49.00 to $52.00. They now have a "buy" rating on the stock.
Low
Report
Exelixis (NASDAQ:EXEL) had its price target raised by analysts at HC Wainwright from $49.00 to $52.00. They now have a "buy" rating on the stock.
1/22
07:31 am
exel
Exelixis: High-Growth Oncology Name Trading At A Discount [Seeking Alpha]
Low
Report
Exelixis: High-Growth Oncology Name Trading At A Discount [Seeking Alpha]
1/15
03:21 pm
exel
Exelixis, Inc. (EXEL): A Bull Case Theory [Yahoo! Finance]
Low
Report
Exelixis, Inc. (EXEL): A Bull Case Theory [Yahoo! Finance]
1/14
11:07 am
exel
Exelixis (NASDAQ:EXEL) was given a new $51.00 price target on by analysts at Truist Financial Corporation.
Low
Report
Exelixis (NASDAQ:EXEL) was given a new $51.00 price target on by analysts at Truist Financial Corporation.
1/11
04:16 pm
exel
Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026 [Yahoo! Finance]
Low
Report
Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026 [Yahoo! Finance]
1/11
04:00 pm
exel
Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026
Low
Report
Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026
1/9
06:11 am
exel
How Natera ctDNA Partnership Around STELLAR-316 At Exelixis (EXEL) Has Changed Its Investment Story [Yahoo! Finance]
Low
Report
How Natera ctDNA Partnership Around STELLAR-316 At Exelixis (EXEL) Has Changed Its Investment Story [Yahoo! Finance]
1/9
12:37 am
exel
Assessing Exelixis (EXEL) Valuation After Zanzalintinib Phase 3 Success And STELLAR-316 Trial Plans [Yahoo! Finance]
Low
Report
Assessing Exelixis (EXEL) Valuation After Zanzalintinib Phase 3 Success And STELLAR-316 Trial Plans [Yahoo! Finance]
1/8
10:57 am
exel
Exelixis (NASDAQ:EXEL) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Exelixis (NASDAQ:EXEL) had its "buy" rating reaffirmed by analysts at HC Wainwright.
1/8
08:21 am
exel
Is It Time To Reassess Exelixis (EXEL) After Strong Multi-Year Share Price Gains [Yahoo! Finance]
Medium
Report
Is It Time To Reassess Exelixis (EXEL) After Strong Multi-Year Share Price Gains [Yahoo! Finance]
1/8
08:02 am
exel
Exelixis (NASDAQ:EXEL) had its "equal weight" rating reaffirmed by analysts at Morgan Stanley. They now have a $48.00 price target on the stock, up previously from $45.00.
Medium
Report
Exelixis (NASDAQ:EXEL) had its "equal weight" rating reaffirmed by analysts at Morgan Stanley. They now have a $48.00 price target on the stock, up previously from $45.00.
1/7
09:18 am
exel
Natera to work with Exelixis on latter's zanzalintinib phase 3 trial [Seeking Alpha]
Medium
Report
Natera to work with Exelixis on latter's zanzalintinib phase 3 trial [Seeking Alpha]
1/7
08:35 am
exel
Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer [Yahoo! Finance]
Medium
Report
Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer [Yahoo! Finance]